Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study

被引：0
|
作者：
Dyer, MJS
Buckby, E
Fermahan, P
Walewska, R
Kennedy, B
机构：
[1] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England
[2] Univ Leicester, Dept Haematol, Leicester, Leics, England
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2959
引用
收藏
页码：830A / 830A
页数：1
相关论文
共 50 条
  • [31] Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium
    Zent, CS
    Chen, JB
    Kurten, RC
    Kaushal, GP
    Lacy, HM
    Schichman, SA
    LEUKEMIA RESEARCH, 2004, 28 (05) : 495 - 507
  • [32] CAMPATH-1H induces apoptosis in human chronic lymphocytic leukemia cells (CLL) in vitro independent of complement mediated lysis or Fcγ receptor ligation.
    Byrd, JC
    Shinn, CA
    Jansure, J
    Hydom, C
    Pearson, MD
    Flinn, IW
    Grever, MR
    BLOOD, 1999, 94 (10) : 126A - 126A
  • [33] Peripheral blood (PB), bone marrow (BM) and flow cytometric (FC) changes in patients with chronic lymphocytic leukemia (CLL) treated with Campath-1H and Rituximab
    Lal, A
    Nabhan, C
    Rosen, S
    Goolsby, C
    Peterson, L
    LABORATORY INVESTIGATION, 2002, 82 (01) : 249A - 249A
  • [34] Peripheral blood (PB), bone marrow (BM) and flow cytometric (FC) changes in patients with chronic lymphocytic leukemia (CLL) treated with Campath-1H and Rituximab
    Lal, A
    Nabhan, C
    Rosen, S
    Goolsby, C
    Peterson, L
    MODERN PATHOLOGY, 2002, 15 (01) : 249A - 249A
  • [35] Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period
    Pangalis, GA
    Dimopoulou, MN
    Angelopoulou, MK
    Tsekouras, CH
    Siakantaris, MP
    MEDICAL ONCOLOGY, 2000, 17 (01) : 70 - 73
  • [36] Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine
    Montillo, M
    Cafro, AM
    Tedeschi, A
    Brando, B
    Oreste, P
    Veronese, S
    Rossi, V
    Cairoli, R
    Pungolino, E
    Morra, E
    HAEMATOLOGICA, 2002, 87 (07) : 695 - 700
  • [37] TREATMENT WITH CAMPATH-1H ANTIBODY IN PATIENTS WITH RELAPSED NON-HODGKIN-LYMPHOMA AND CHRONIC LYMPHOCYTIC-LEUKEMIA
    BROWN, PD
    GEISLER, CH
    NISSEN, NI
    BLOOD, 1994, 84 (10) : A653 - A653
  • [38] Liver function abnormalities following alemtuzumab (Campath-1H): A previously unrecognised first dose effect
    Milojkovic, D
    Lim, ZY
    Britten, C
    Chappell, J
    Ho, A
    Duarte, R
    Pagliuca, A
    Devereux, S
    Mufti, GJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 79 - 79
  • [39] Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis.
    Rai, KR
    Coutre, S
    Rizzieri, D
    Gribben, JG
    Flinn, I
    Rabinowe, S
    Keating, MJ
    BLOOD, 2001, 98 (11) : 365A - 365A
  • [40] Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period
    GA Pangalis
    MN Dimopoulou
    MK Angelopoulou
    CH Tsekouras
    MP Siakantaris
    Medical Oncology, 2000, 17 : 70 - 73
12345